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Background:  Percutaneous  coronary  intervention  for lesions  with  small  vessel  diameter  may have  high
event rates.  Although  drug-eluting  stents  reduce  the  risk  of  restenosis,  the  long-term  efﬁcacy  of  drug-
eluting  stent  implantation  in small  vessels  is  unclear.
Methods  and  results:  We  reviewed  the  data  of Cypher  Stent  Japan  Post-Marketing  Surveillance  Registry
including  2356  lesions  of  1959  patients,  and  retrospectively  investigated  the  angiographic  outcomes
at  8 months,  and  the clinical  outcomes  at 1800  days  after  sirolimus-eluting  stent  (SES)  implantation  in
vessels  with  diameter  less  than 2.5  mm  (small  vessel  group)  compared  to  that  with  diameter  of  2.5  mm  or
more  (non-small  vessel  group).  The  rate  of  major  adverse  cardiac  events  (MACE)  at  1800  days  was  slightly
higher  in the  small  vessel  group  than  in  the non-small  vessel  group,  but  not  statistically  signiﬁcant  (24.4%
vs  21.0%,  p  =  0.086).  The  rate  of target  lesion  revascularization  was  higher  in the  small  vessel  group  than  in
the non-small  vessel  group  (10.2%  vs  6.4%,  p = 0.004).  The  rate  of  stent  thrombosis  was  almost  the same  in
the two  groups.  Multivariate  Cox  hazard  model  analysis  revealed  that a  vessel  diameter  less than  2.5  mm
was  not  an independent  risk  factor  for  MACE.
Conclusion:  SES  implantation  for vessels  with  diameter  less  than  2.5  mm  is  safe  and  provides  good  long-
term outcomes.
©  2012  Japanese  College  of  Cardiology.  Published  by  Elsevier  Ltd.  All rights  reserved.. Introduction
It has been reported that the long-term outcomes of percu-
aneous coronary intervention (PCI) for small vessel diseases are
orse than those for large vessel diseases in the bare metal stent
ra [1,2]. Drug-eluting stents (DESs) have signiﬁcantly reduced the
ates of restenosis, and target lesion revascularization (TLR) [3,4].
ut most of the studies included only lesions with a reference vessel
iameter of 2.5 mm or more. Therefore, the safety and the efﬁcacy
f DES implantation in small vessel disease are still unclear, and
ESs with a diameter less than 2.5 mm are not available in Japan.
irolimus-eluting stent (SES) is a ﬁrst-generation DES, and its efﬁ-
acy for the prevention of restenosis has been compared to that of
he subsequent DES.
In this study, to evaluate the long-term safety and efﬁcacy of SES
mplantation in small vessel disease, we retrospectively investi-
ated the 240-day angiographical outcomes, and 1800-day clinical
∗ Corresponding author. Tel.: +81 3 3588 1111; fax: +81 3 3582 7068.
E-mail address: hafujimoto-circ@umin.ac.jp (H. Fujimoto).
914-5087/$ – see front matter © 2012 Japanese College of Cardiology. Published by Else
ttp://dx.doi.org/10.1016/j.jjcc.2012.08.005outcomes of SES implantation in small vessels with reference vessel
diameter less than 2.5 mm based on multi-center registry data.
2. Patients and methods
2.1. Subjects
Cypher Stent Japan Post-Marketing Surveillance Registry (J-
PMS) is a post-marketing surveillance registry that was  mandated
by the Japanese government to fulﬁll one of the regulatory approval
conditions. The major objective of the registry is to evaluate the
efﬁcacy and safety of SES in Japanese patients in daily practical use.
It was  planned to enroll a total of 2000 cases implanted with SES
consecutively from September 2004 through September 2005 at
50 hospitals in Japan. Angiographical follow-up at 8 months was
mandated.
We  reviewed the data of the registry enrolling 2458 de novo
lesions of 2050 patients, and compared the angiographical out-
comes at 8 months, and the clinical outcomes at 1800 days after
SES implantation in the vessels with reference diameter less than
2.5 mm (small vessel group) to those in the vessels with reference
diameter of 2.5 mm  or more (non-small vessel group).
vier Ltd. All rights reserved.
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.2. Data collection and management
The post-marketing surveillance databases were developed by
ohnson & Johnson K.K. in Japan. Detailed demographics, clinical,
ngiographic, and procedural information including complications
ere gathered for each patient. The data were entered into case
eport forms by participating sites and collected by Johnson & John-
on K.K. Follow-up data were collected at 3, 8, 12, months and
ollowed up to 5 years. Angiographic data on 1063 of 2458 lesions
ere analyzed by an independent core laboratory (Cardiocore,
okyo, Japan), and the remaining angiograms were analyzed by
n-site quantitative coronary angiography (QCA). An independent
afety and efﬁcacy evaluation committee adjudicated all reported
nd suspected major adverse cardiovascular events (MACE) deﬁned
s death, myocardial infarction (MI), and TLR by PCI or by coronary
rtery bypass graft surgery (CABG); stent thromboses; and target
essel revascularization (TVR) by PCI or CABG. The adjudications
ere based on the information contained in the case report form
nd on the responses to queries addressed to the participating study
ite.
MI was classiﬁed as Q wave and non-Q wave by the physicians’
iscretion on the basis of electrocardiographic changes and/or a rise
n creatine kinase enzyme concentration above twice the upper
ormal limit. If no information or judge classiﬁcation of MI  was
vailable, it was  classiﬁed as unidentiﬁed. TLR were based on the
IRIUS trial protocol deﬁnition and, all reported re-interventions
nside the implanted stent or within 5 mm proximal or distal to
he stent were classiﬁed as TLR. Other repeated PCI in the same
essel was recorded as non-target lesion TVR. Stent thrombosis was
lassiﬁed based on Academic Research Consortium (ARC) deﬁnition
s ‘deﬁnite’ or ‘probable’ [5].
.3. Statistical analysis
Data are expressed as mean ± SD for continuous variables and
s frequencies for the categorical variables. Continuous variables
ere compared using the Wilcoxon rank sum test. Binary variables
ere compared by means of Fisher’s exact test. Time-to-event data
ere analyzed using the Kaplan–Meier method and log rank test.
tatistical signiﬁcance was  deﬁned as a p-value of less than 0.05.
o evaluate the independent risk factors for MACE, we performed
ultivariate analysis using Cox’s proportional hazard model (step-
ise: p = 0.001). All statistical analyses were performed using JMP
ersion 8.0 (SAS Institute, Cary, NC, USA).
2050 patients/ 2458  lesion s enrol 
from Se ptembe r 1st 2004 to 
1016 patients/ 1139  lesion s were  
allocated  in the Pre RVD< 2.5 mm gro up 
1959 patients/  2,356 lesio 
2005 lesions underwent follow-up CAG 
1853 patients  were foll owe d  a 
ig. 1. Flow chart of the analysis. Cypher-J-PMS: Cypher Stent Japan Post-Marketing Surv
ollow  up.rdiology 61 (2013) 31–37
3. Results
3.1. Baseline patient characteristics
A total of 2458 lesions in 2050 patients were enrolled in the
Cypher J-PMS, but 102 lesions of 91 patients were excluded because
the reference vessel diameters before PCI were not evaluated in
them. A total of 2356 lesions in 1959 patients were analyzed. A
total of 1139 lesions in 1016 patients were allocated to the small
vessel group, and 1217 lesions in 943 patients were allocated to the
non-small vessel group (Fig. 1). Baseline patient characteristics are
shown in Table 1. The number of males was  signiﬁcantly lower in
the small vessel group than in the non-small vessel group (72.4% vs
78.5%, p = 0.002). The number of diabetic patients was signiﬁcantly
higher in the small vessel group than in the non-small vessel group
(49.0% vs 38.1%, p < 0.001).
3.2. Lesion and procedural characteristics
Lesion and procedural characteristics are shown in Table 2.
Lesion distribution and angulation were different between the
small vessel group and the non-small vessel group. Total stent
length was signiﬁcantly longer in the small vessel group than
in the non-small vessel group (29.4 ± 14.6 mm vs 27.1 ± 13.7 mm,
p < 0.001, Table 2). More lesions underwent balloon dilatation
before stent implantation in the small vessel group than in the non-
small vessel group (81.5% vs 73.7%, p < 0.001). Maximum pressure
at stent deployment was lower in the small vessel group than in the
non-small vessel group (15.3 ± 3.5 atm vs 16.7 ± 3.4 atm, p < 0.001).
3.3. Angiographical ﬁndings and outcomes
Two thousand and ﬁve lesions underwent follow-up angiogra-
phy. The follow-up rate was  85.1% by lesion. Median follow-up
period was  234 days. Angiographical outcomes are shown in
Table 3. Reference vessel diameter before PCI was 2.08 ± 0.31 mm
in the small vessel group, and 3.02 ± 0.43 mm in the non-small
vessel group, respectively. Lesion length was  almost same in the
two groups (17.2 ± 10.0 mm vs 17.6 ± 10.2 mm). Late loss was sig-
niﬁcantly lower in the small vessel group than in the non-small
vessel group (0.11 ± 0.57 mm vs 0.20 ± 0.58 mm,  p < 0.001). Binary
restenosis rate in the small vessel group was signiﬁcantly higher
than that in the non-small vessel group (12.5% vs 5.5%, p < 001), but
was much lower than that of BMS  previously reported [1,2].
led in the Cyp her  J-PMS  
September 30th 2005 
943 patients/ 1217  lesion s wer e  
allocated  in the Pre RVD ≥2.5mm  group  
Excluding 91p atients/ 102 lesion s 
 who were NOT evaluated Pre -RVD  
ns were  anal yzed 
 at 240 days (F.U. rate 85.1% by lesion) 
t 1800 days (F.U. rate: 94.6 %) 
eillance Registry; RVD: reference vessel diameter; CAG: coronary angiography; FU:
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Table  1
Baseline patient characteristics.
Number of patients Pre RVD < 2.5 mm (n = 1016) Pre RVD ≥ 2.5 mm (n = 943) p-Value
Age at enrollment, years 67.1 ± 9.9 67.0 ± 10.1 0.614
Age  ≥75 years 253 (24.9) 224 (23.8) 0.563
Male,  n (%) 736 (72.4) 740 (78.5) 0.002
Ejection fraction <30%, n (%) 30 (3.5) 31 (3.9) 0.696
Indication at enrollment
AP, n (%) 564 (55.5) 499 (52.9) 0.257
UAP,  n (%) 123 (12.1) 147 (15.6) 0.026
AMI,  n (%) 36 (3.5) 37 (3.9) 0.721
RMI,  n (%) 20 (2.0) 28 (3.0) 0.188
OMI,  n (%) 127 (12.5) 123 (13.0) 0.735
Silent ischemia, n (%) 138 (13.6) 105 (11.1) 0.115
Other, n (%) 8 (0.8) 4 (0.4) 0.390
Previous MI,  n (%) 394 (38.8) 347 (36.8) 0.376
Previous PCI, n (%) 587 (57.8) 531 (56.3) 0.523
Previous CABG, n (%) 81 (8.0) 75 (8.0) 1.000
Diabetes, n (%) 498 (49.0) 359 (38.1) <0.001
Dialysis, n (%) 42 (4.1) 61 (6.5) 0.025
Hypertension, n (%) 698 (68.7) 667 (70.7) 0.350
Hyperlipidemia, n (%) 571 (56.2) 543 (57.6) 0.553
Peripheral artery disease, n (%) 74 (7.3) 51 (5.4) 0.096
Cerebral vascular disease, n (%) 89 (8.8) 65 (6.9) 0.131
BMI  (kg/m2) 23.8 ± 3.2 24.4 ± 3.3 <0.001
Family history of CAD, n (%) 69 (6.8) 63 (6.7) 0.928
Current smoking, n (%) 179 (17.6) 190 (20.1) 0.165
Multi-vessel disease, n (%) 449 (44.2) 354 (37.5) 0.003
RVD: reference vessel diameter; AP: angina pectoris; UAP: unstable angina pectoris; AMI: acute myocardial infarction; RMI: recent myocardial infarction, that is, myocardial
infarction that occurred more than 48 h ago and within 30 days; OMI: old myocardial infarction; MI:  myocardial infarction; PCI: percutaneous coronary intervention; CABG:
coronary artery bypass graft surgery; BMI: body mass index; CAD: coronary artery disease. Cerebral vascular disease includes cerebral infarction and cerebral hemorrhage.
Table  2
Lesion and procedure characteristics.
Number of lesions Pre RVD < 2.5 mm Pre RVD ≥2.5 mm p-Value
(n  = 1139) (n = 1217)
Target vessel
RCA, n (%) 250 (21.9) 465 (38.2) <0.001
LAD,  n (%) 586 (51.5) 479 (39.4) <0.001
LCX,  n (%) 291 (25.5) 209 (17.2) <0.001
LMT,  n (%) 0 (0.0) 60 (4.9) 0.010
HL,  n (%) 12 (1.1) 4 (0.3) 0.043
ACC/AHA type B2/C, n (%) 913 (80.2) 972 (80.3) 1.000
De  novo, n (%) 889 (78.1) 971 (79.8) 0.312
In  stent restenosis, n (%) 180 (15.8) 165 (13.6) 0.130
Moderate/severe calciﬁcation, n (%) 188 (16.5) 218 (17.9) 0.383
Concentric, n (%) 541 (48.1) 512 (42.8) 0.012
Lesion angulation ≥45◦ , n (%) 139 (12.2) 222 (18.2) <0.001
Bifurcation, n (%) 382 (33.5) 392 (32.2) 0.510
Ostial, n (%) 131 (11.5) 264 (21.7) <0.001
Chronic total occlusion, n (%) 47 (4.1) 31 (2.5) 0.038
Pre  dilatation, n (%) 928 (81.5) 897 (73.7) <0.001
Rotablator usage, n (%) 41 (3.6) 50 (4.1) 0.593
IVUS  usage, n (%) 836 (73.4) 879 (72.2) 0.547
Total  stent length, mm 29.4 ± 14.6 27.1 ± 13.7 <0.001
Used  stent diameter, mm 2.66 ± 0.33 3.14 ± 0.34 <0.001
#  of stents per lesion 1.4 ± 0.6 1.3 ± 0.6 <0.001
Max  pressure at deployment, atm 15.3 ± 3.5 16.7 ± 3.4 <0.001
Post  dilatation, n (%) 548 (48.1) 551 (45.3) 0.173
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mVD: reference vessel diameter; RCA: right coronary artery; LAD: left anterior desc
CC:  American College of Cardiology; AHA: American Heart Association; IVUS: intr
.4. Association of the vessel diameter measured by QCA with
hat measured by intravascular ultrasound
We  analyzed the association of the vessel diameter measured
y intravascular ultrasound (IVUS) with that measured by QCA. We
ould obtain both the IVUS data and QCA data of only 32 lesions. In
any reference lesions of which % diametric stenosis was  almost
%, plaques were detected by IVUS as shown in Fig. 2. As with
he 32 lesions, mean reference vessel diameter measured by QCA
as 2.31 ± 0.72 mm,  while mean minimal diameter of those lesions
easured by IVUS was 2.44 ± 0.89 mm (p < 0.001, angiographicalg artery; LCX: left circumﬂex artery; LMT: left main trunk; HL: high lateral branch;
lar ultrasound.
reference vessel diameter vs the vessel diameter measured by
IVUS).
3.5. Antiplatelet therapy
All of the patients took both aspirin and thienopyridine at enroll-
ment. Some of the patients stopped receiving thienopyridine, but
all of the patients continued taking aspirin. The percentages of the
patients receiving dual antiplatelet therapy during the follow-up
period are shown in Table 4.
34 H. Fujimoto et al. / Journal of Cardiology 61 (2013) 31–37
Fig. 2. An example of intravascular ultrasound (IVUS) ﬁndings of the lesion which seems to be normal by angiography. Although the marked lesion seems normal by
angiography (left), IVUS reveals plaque distribution in this site (right). Therefore, angiography tends to underestimate the reference vessel diameter compared to IVUS.
Table  3
Angiographical ﬁndings and outcomes.
Number of lesions Pre
RVD < 2.5 mm
(n = 1139)
Pre
RVD ≥ 2.5 mm
(n = 1217)
p-Value
Lesion length, mm 17.2 ± 10.0 17.6 ± 10.2 0.163
RVD before procedure, mm 2.08 ± 0.31 3.02 ± 0.43 0.000
MLD, mm
Before procedure 0.62 ± 0.37 0.93 ± 0.50 <0.001
After procedure 1.91 ± 0.55 2.54 ± 0.61 <0.001
At  240 days 1.81 ± 0.61 2.36 ± 0.66 <0.001
%DS (%)
Before procedure 70.7 ± 16.5 69.6 ± 15.8 0.155
After procedure 21.8 ± 15.2 16.9 ± 11.8 <0.001
At  240 days 27.3 ± 20.0 21.7 ± 16.7 <0.001
Acute gain, mm 1.29 ± 0.59 1.62 ± 0.68 <0.001
Late loss, mm 0.11 ± 0.57 0.20 ± 0.58 <0.001
Binary restenosis, n (%) 122/973 (12.5) 57/1032 (5.5) <0.001
Initial success rate, n (%),
per lesion
1113 (97.7) 1199 (98.5) 0.523
Complication ratea, n (%),
per patient
42 (4.2) 41 (4.3) 0.621
RVD: reference vessel diameter; MLD: minimal lumen diameter; %DS: percent diam-
eter stenosis.
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Table 5
Clinical outcomes at 1800 days.
Number of patients Pre
RVD < 2.5 mm
(n = 951)
Pre RVD
≥2.5 mm
(n = 902)
p-Value
MACE, n (%) 232 (24.4) 189 (21.0) 0.086
Death, n (%) 123 (12.9) 120 (13.3) 0.837
Cardiac death, n (%) 45 (4.7) 42 (4.7) 1.000
Non  cardiac death, n (%) 78 (8.2) 78 (8.7) 0.739
MI,  n (%) 33 (3.5) 30 (3.3) 0.899
Q-wave MI,  n (%) 18 (1.9) 7 (0.8) 0.044
Non Q-wave MI,  n (%) 10 (1.1) 20 (2.2) 0.064
Unknown MI, n (%) 5 (0.5) 3 (0.3) 0.727
Emergency CABG, n (%) 2 (0.2) 1 (0.1) 1.000
TLR  by patient, n (%) 106 (11.2) 67 (7.4) 0.007
TLR  by lesion, n (%) 108 (10.2) 78 (6.7) 0.004
TVR, n (%) 172 (18.1) 117 (13.0) 0.003
TVF, n (%) 217 (22.8) 149 (16.5) 0.001
Stent thrombosis based on ARC, n (%)
Deﬁnite + probable 12 (1.26) 11 (1.22) 1.000
Deﬁnite 9 (0.95) 8 (0.89) 1.000
Probable 3 (0.32) 3 (0.33) 1.000
RVD: reference vessel diameter; MACE: major adverse cardiovascular event; MI:a Complications include procedure-related vascular injury, major bleeding, renal
ailure, myocardial infarction, and cerebral infarction.
.6. Clinical outcomes
Clinical outcomes at 1800 days are shown in Table 5. The follow-
p rate was 94.6% by patient (1853/1959). The median follow-up
eriod was 1781 days. The rate of MACE at 1800 days was slightly
igher in the small vessel group than in the non-small vessel group,
ut this was not statistically signiﬁcant (24.4% vs 21.0%, p = 0.086).
he rate of TLR was higher in the small vessel group than in the
on-small vessel group (10.2% vs 6.4%, p = 0.004). But the rate was
ower than that of BMS  reported by previous studies [1,2]. The rate
f stent thrombosis was also not signiﬁcantly different between
able 4
ercentage of the patients who received dual antiplatelet therapy during the follow-
p  period.
0 days 1 year 2 years 3 years 4 years 5 years
Pre RVD < 2.5 mm 100 93.9 86.3 81.2 78.4 75.1
Pre  RVD ≥2.5 mm 100 92.8 84.7 80.1 77.3 71.4
VD: reference vessel diameter.myocardial infarction; CABG: coronary artery bypass graft; TLR: target lesion revas-
cularization; TVR: target vessel revascularization; TVF: target vessel failure; ARC:
Academic Research Consortium.
the two  groups (1.26% in the small group vs 1.22% in the non-small
vessel group, p = 1.00).
Event-free survival curves for MACE and TLR are shown in Fig. 3.
3.7. Independent risk factors for MACE and TLR
To correct the baseline differences that may affect the results
of the analysis, we performed multivariate analysis using Cox’s
proportional hazard model (stepwise: p = 0.001). Univariate anal-
ysis, and multivariate analysis revealed that the reference vessel
diameter <2.5 mm was not an independent risk factor for MACE
[hazard ratio (HR) 1.12, 95% conﬁdence interval (CI): 0.918–1.366,
p = 0.263]. But univariate analysis, and multivariate analysis
revealed that the reference vessel diameter <2.5 mm was an inde-
pendent risk factor of TLR (HR 1.667, 95% CI: 1.228–2.264, p = 0.001,
Table 6).4. Discussion
The major ﬁndings of this study are that SES implantation in
small vessels with reference diameter less than 2.5 mm is safe, and
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fig. 3. Event-free survival curves for MACE and TLR. (A) MACE-free curve, by patient.
B) TLR-free curve, by patient. RVD: reference vessel diameter; MACE: major adverse
ardiac event; TLR: target lesion revascularization.
rovide good long-term outcomes. This study also provides the ﬁrst
ata of 5-year follow-up of DES implantation in Japan. Thus far, sev-
ral studies have suggested the possibility of late catch-up after DES
mplantation [6–8]. Our data show that even if late catch-up phe-
omenon occurs after SES implantation, the long-term outcomes
f SES implantation are good and the rates of MACE were low even
 years after implantation.
It has been reported that small vessel diameter increases the risk
f restenosis and target vessel failure after BMS  implantation [1,2].
here is much evidence that DES suppresses neointima formation,
nd signiﬁcantly reduces restenosis compared to BMS. But most
f the subjects in the previous randomized controlled trials had
esions with vessel diameter of 2.5 mm  or more. The efﬁcacy of DES
able 6
nivariate and multivariate analyses of the risk factors for major adverse cardiac events (
Risk Univariate analysis 
HR (95%CI) 
(A)
Pre RVD < 2.5 mm 1.140 (0.941–1.379) 
Dialysis 3.900 (2.964–5.131) 
Age  ≥75 years old 1.732 (1.425–2.105) 
Ostial 1.382 (1.106–1.726) 
PAD  1.750 (1.290–2.375) 
CVD  1.500 (1.109–2.030) 
Multi-vessel disease 1.327 (1.102–1.597) 
Previous CABG 1.733 (1.312–2.287) 
Lesion length >30 mm 1.338 (1.021–1.753) 
(B)
Pre  RVD <2.5 mm 1.545 (1.155–2.068) 
Dialysis 3.534 (2.305–5.420) 
Ostial 1.640 (1.188–2.265) 
Lesion length >30 mm 1.667 (1.132–2.455) 
Previous PCI 1.606 (1.195–2.159) 
Diabetes 1.606 (1.213–2.125) 
R: hazard ratio; CI: conﬁdence interval; RVD: reference vessel diameter; PAD: peripheral
CI:  percutaneous coronary intervention Cox’s proportional hazard model (stepwise: p = 0
rom  patient background and lesion characteristics.rdiology 61 (2013) 31–37 35
for small vessel diseases with vessel diameter less than 2.5 mm has
not been clariﬁed. Late loss will critically affect restenosis in small
vessel disease. In our study, late loss in the small vessel group was
as low as that in the non-small vessel group. Therefore, small vessel
disease may  receive much beneﬁt from DES implantation.
In our study, the rate of stent thrombosis in the small vessel
group was almost the same as that in the non-small vessel group. It
is reported that neointima coverage of SES is incomplete for several
years after implantation, and sometimes subclinical thrombus is
detected by angioscope or optical coherence tomography [9,10].
Therefore, stent thrombosis has been a major concern after DES
implantation [11]. Thus far, several mechanisms and risk factors
for stent thrombosis after DES implantation have been suggested
[12–15]. Some studies imply an association between small vessel
diameter and stent thrombosis [12], but others do not [13,14].  As
we previously reported in the 1-year follow-up of J-PMS registry
[16], our study showed that the risk for stent thrombosis is low
even 5 years after SES implantation, and does not increase even if
SES are implanted in vessels with a diameter less than 2.5 mm.  The
low incidence rate of stent thrombosis in our study may be partly
due to the careful out-of-hospital follow-up and the continuation
of dual antiplatelet therapy including aspirin and thienopyridine in
Japan.
The reference vessel diameter in the small vessel group was
2.08 mm in this study. In this registry, IVUS was used in about 70%
of lesions. Angiographical reference vessel diameter was smaller
than the vessel diameter measured by IVUS. If IVUS is performed,
stent size is determined based on the vessel diameter measured by
IVUS. That may  be the reason why the stent with the diameter of
2.5 mm was implanted in the vessels with the mean reference ves-
sel diameter of 2.08 mm.  When we implant stents in small vessels,
it is important not to make dissection or rupture of the vessels. That
may  be the reason why predilatation was more frequent, and max-
imum pressure of stent deployment was lower in the small vessel
group than in the non-small vessel group. If SES with a diameter of
2.25 mm or less were available in Japan, PCI to the small vessel may
become safer and bring about good long-term outcomes.
In this study, baseline characteristics were different between thecentage of diabetes patients was  signiﬁcantly higher in the small
vessel group than in the non-small vessel group. Second, the per-
centage of ostial lesions was  higher in the non-small vessel group
A) and target lesion revascularization (B).
Multivariate analysis
p-Value HR (95%CI) p-Value
0.180 1.120 (0.918–1.366) 0.263
<0.001 4.021 (3.013–5.368) <0.001
<0.001 1.686 (1.367–2.079) <0.001
0.004 1.384 (1.092–1.754) 0.007
<0.001 1.510 (1.096–2.080) 0.012
0.009 1.442 (1.049–1.983) 0.024
0.003 1.258 (1.032–1.534) 0.023
<0.001 1.378 (1.009–1.883) 0.044
0.035 1.304 (0.986–1.724) 0.063
0.003 1.667 (1.228–2.264) 0.001
<0.001 3.462 (2.196–5.457) <0.001
0.003 1.839 (1.307–2.587) 0.001
0.010 1.686 (1.129–2.517) 0.011
0.002 1.472 (1.073–2.020) 0.017
0.001 1.376 (1.016–1.864) 0.039
 artery disease; CVD: cerebral vascular disease; CABG: coronary artery bypass graft;
.100) was  used for univariate and multivariate analysis. Variables were composed
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han in the small vessel group. Such differences might have affected
he long-term outcomes because diabetes is an independent risk
actor for TLR after SES implantation [17], and the ostial lesions may
e more critical than the distal lesions for the patient. But multi-
ariate analysis revealed that the vessel diameter less than 2.5 mm
as not associated with MACE, although it increases the risk of TLR.
Today, several types of DES are available for clinical use. SES is
he ﬁrst DES that came into clinical use. The safety and efﬁcacy of
he subsequent DESs have been compared to SES, but their long-
erm outcomes are not much different from SES [18–20].  Therefore,
he results of our study may  be applied to most of the other DESs,
nd it is desired that DES with a diameter less than 2.5 mm becomes
vailable in Japan.
.1. Study limitations
This study was a retrospective study with a small number of
atients. Although we performed multivariate analysis to correct
he difference in the baseline characteristics between the two
roups, a randomized study with a larger patient population will be
ecessary to induce more conﬁdent evidence. In this study, about
alf of the angiographic data were analyzed by a core laboratory,
nd the remaining data were analyzed by on-site QCA, because it
as impossible to perform all of the analysis in the core laboratory.
here may  be some operator bias in our data.
. Conclusion
The long-term outcomes of SES implantation are good even
 years after stent implantation. The outcomes are not different
etween the SES implantation in the vessels with reference diam-
ter less than 2.5 mm and in the vessels with diameter of 2.5 mm
r more.
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